• Je něco špatně v tomto záznamu ?

Dissolution of Oral Solid Dosage Formulations: Surrogate Models and Real-time Release

M. Dumarey, TM. Carducci, MJ. Walworth, CJ. Smith, S. García-Muñoz, S. Nielsen, S. Jacquart, AT. da Silva, S. Altan, M. Otava, Y. Lan, N. Zaborenko

. 2025 ; 27 (5) : 115. [pub] 20250627

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015243

In vitro dissolution testing is commonly performed to ensure that oral solid dosage medicines are of high quality and will achieve their targeted in vivo performance. However, this testing is time and material consuming. Therefore, pharmaceutical companies have been developing predictive dissolution models (PDMs) for drug product release based on fast at- and/or on-line measurements, including real-time release testing of dissolution (RTRT-D). Recently, PDMs have seen acceptance by major regulatory bodies as release tests for the dissolution critical quality attribute. In this paper, several methodologies are described to develop and validate a fit-for-purpose model, then to implement it as a surrogate release test for dissolution. These approaches are further exemplified by real-life case studies, which demonstrate that PDMs for release are not only viable but more sustainable than in vitro dissolution testing and can significantly accelerate drug product release. The rise of continuous manufacturing within the pharmaceutical industry further favors the implementation of real-time release testing. Therefore, a steep uptake of PDMs for release is expected once this methodology is globally accepted. To that end, it is advantageous for global regulators and pharmaceutical innovators to coalesce around a harmonized set of expectations for development, validation, implementation, and lifecycle of PDMs as part of drug product release testing.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015243
003      
CZ-PrNML
005      
20250731090850.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1208/s12248-025-01102-0 $2 doi
035    __
$a (PubMed)40579614
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dumarey, Melanie $u Global Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden. melanie.dumarey@astrazeneca.com $1 https://orcid.org/0009000137429009
245    10
$a Dissolution of Oral Solid Dosage Formulations: Surrogate Models and Real-time Release / $c M. Dumarey, TM. Carducci, MJ. Walworth, CJ. Smith, S. García-Muñoz, S. Nielsen, S. Jacquart, AT. da Silva, S. Altan, M. Otava, Y. Lan, N. Zaborenko
520    9_
$a In vitro dissolution testing is commonly performed to ensure that oral solid dosage medicines are of high quality and will achieve their targeted in vivo performance. However, this testing is time and material consuming. Therefore, pharmaceutical companies have been developing predictive dissolution models (PDMs) for drug product release based on fast at- and/or on-line measurements, including real-time release testing of dissolution (RTRT-D). Recently, PDMs have seen acceptance by major regulatory bodies as release tests for the dissolution critical quality attribute. In this paper, several methodologies are described to develop and validate a fit-for-purpose model, then to implement it as a surrogate release test for dissolution. These approaches are further exemplified by real-life case studies, which demonstrate that PDMs for release are not only viable but more sustainable than in vitro dissolution testing and can significantly accelerate drug product release. The rise of continuous manufacturing within the pharmaceutical industry further favors the implementation of real-time release testing. Therefore, a steep uptake of PDMs for release is expected once this methodology is globally accepted. To that end, it is advantageous for global regulators and pharmaceutical innovators to coalesce around a harmonized set of expectations for development, validation, implementation, and lifecycle of PDMs as part of drug product release testing.
650    _2
$a lidé $7 D006801
650    _2
$a aplikace orální $7 D000284
650    _2
$a farmaceutická chemie $x metody $7 D002626
650    _2
$a příprava léků $7 D004339
650    12
$a uvolňování léčiv $7 D065546
650    _2
$a léčivé přípravky $x chemie $x aplikace a dávkování $7 D004364
650    _2
$a rozpustnost $7 D012995
650    _2
$a schvalování léčiv $7 D017277
655    _2
$a časopisecké články $7 D016428
700    1_
$a Carducci, Tessa M $u Analytical Commercialization Technology, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, United States of America
700    1_
$a Walworth, Matthew J $u Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN, 46285, United States of America
700    1_
$a Smith, Casey J $u Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN, 46285, United States of America
700    1_
$a García-Muñoz, Salvador $u Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN, 46285, United States of America
700    1_
$a Nielsen, Sarah $u Janssen Supply Chain, Johnson & Johnson, New Brunswick, NJ, United States of America
700    1_
$a Jacquart, Sylvaine $u Janssen Pharmaceutica NV, Beerse, Belgium
700    1_
$a da Silva, Ana Tavares $u Janssen Pharmaceutica NV, Beerse, Belgium
700    1_
$a Altan, Stan $u Manufacturing and Applied Statistics, Janssen Pharmaceutical R&D LLD, Raritan, NJ, 08869, United States of America
700    1_
$a Otava, Martin $u Manufacturing and Applied Statistics, Janssen-Cilag S.R.O., Prague, Czechia
700    1_
$a Lan, Yanmei $u Analytical Development, Pharmaceutical Sciences, Takeda, Cambridge, MA, 02139, United States of America
700    1_
$a Zaborenko, Nikolay $u Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN, 46285, United States of America
773    0_
$w MED00163142 $t The AAPS journal $x 1550-7416 $g Roč. 27, č. 5 (2025), s. 115
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40579614 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090845 $b ABA008
999    __
$a ok $b bmc $g 2366231 $s 1252368
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 27 $c 5 $d 115 $e 20250627 $i 1550-7416 $m The AAPS journal $n AAPS J $x MED00163142
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace